Listed

Actinium Pharmaceuticals, Inc.

ATNMNYSECIK 1388320HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$35.0m, Q2 FY2026
Operating income$27.6m, Q2 FY2026
Net income$27.9m, Q2 FY2026
Actinium Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.1Revenue, Q3 FY2025, three months to 2025-09-30$90.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figurenot reported35.0Revenue, Q2 FY2026, three months to 2026-06-30$35.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Gross profit$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m11.6Research and development, Q3 FY2023, three months to 2023-09-30$11.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figure8.1Research and development, Q4 FY2023, three months to 2023-12-31$8.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001213900-25-026371. Derived: 12-month figure less the 9-month figure.Report this figure6.6Research and development, Q1 FY2024, three months to 2024-03-31$6.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure8.8Research and development, Q2 FY2024, three months to 2024-06-30$8.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-08, accession 0001213900-25-073743.Report this figure9.8Research and development, Q3 FY2024, three months to 2024-09-30$9.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure4.8Research and development, Q4 FY2024, three months to 2024-12-31$4.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figure7.7Research and development, Q1 FY2025, three months to 2025-03-31$7.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure4.9Research and development, Q2 FY2025, three months to 2025-06-30$4.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure4.2Research and development, Q3 FY2025, three months to 2025-09-30$4.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure4.3Research and development, Q4 FY2025, three months to 2025-12-31$4.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figure4.2Research and development, Q1 FY2026, three months to 2026-03-31$4.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure5.4Research and development, Q2 FY2026, three months to 2026-06-30$5.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Operating income$m(14.4)Operating income, Q3 FY2023, three months to 2023-09-30−$14.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figure(10.3)Operating income, Q4 FY2023, three months to 2023-12-31−$10.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001213900-25-026371. Derived: 12-month figure less the 9-month figure.Report this figure(9.6)Operating income, Q1 FY2024, three months to 2024-03-31−$9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure(12.4)Operating income, Q2 FY2024, three months to 2024-06-30−$12.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-08, accession 0001213900-25-073743.Report this figure(12.6)Operating income, Q3 FY2024, three months to 2024-09-30−$12.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure(7.5)Operating income, Q4 FY2024, three months to 2024-12-31−$7.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figure(16.6)Operating income, Q1 FY2025, three months to 2025-03-31−$16.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure(7.5)Operating income, Q2 FY2025, three months to 2025-06-30−$7.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure(5.7)Operating income, Q3 FY2025, three months to 2025-09-30−$5.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure(6.4)Operating income, Q4 FY2025, three months to 2025-12-31−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figure(5.9)Operating income, Q1 FY2026, three months to 2026-03-31−$5.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure27.6Operating income, Q2 FY2026, three months to 2026-06-30$27.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(13.3)Net income, Q3 FY2023, three months to 2023-09-30−$13.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figure(9.3)Net income, Q4 FY2023, three months to 2023-12-31−$9.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001213900-25-026371. Derived: 12-month figure less the 9-month figure.Report this figure(8.7)Net income, Q1 FY2024, three months to 2024-03-31−$8.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure(11.4)Net income, Q2 FY2024, three months to 2024-06-30−$11.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure(11.6)Net income, Q3 FY2024, three months to 2024-09-30−$11.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure(6.7)Net income, Q4 FY2024, three months to 2024-12-31−$6.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figure(15.9)Net income, Q1 FY2025, three months to 2025-03-31−$15.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure(6.9)Net income, Q2 FY2025, three months to 2025-06-30−$6.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure(5.1)Net income, Q3 FY2025, three months to 2025-09-30−$5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure(5.9)Net income, Q4 FY2025, three months to 2025-12-31−$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figure(5.5)Net income, Q1 FY2026, three months to 2026-03-31−$5.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure27.9Net income, Q2 FY2026, three months to 2026-06-30$27.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Diluted EPS$ per share(0.49)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figurenot reported(0.31)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure(0.38)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-08, accession 0001213900-25-073743.Report this figure(0.37)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figurenot reported(0.51)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure(0.22)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure(0.16)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figurenot reported(0.18)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure0.89Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.89 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Basic EPS$ per share(0.49)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.49 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figurenot reported(0.31)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure(0.38)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-08, accession 0001213900-25-073743.Report this figure(0.37)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figurenot reported(0.51)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure(0.22)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure(0.16)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figurenot reported(0.18)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure0.89Basic EPS, Q2 FY2026, three months to 2026-06-30$0.89 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure

Balance sheet

Cash and equivalents$36.5m, Q2 FY2026
Shareholders' equity$30.3m, Q2 FY2026
Actinium Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m83.0Cash and equivalents, Q3 FY2023, at 2023-09-30$83.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-02, accession 0001213900-23-082459.Report this figure76.7Cash and equivalents, FY2023, at 2023-12-31$76.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0001213900-25-026371.Report this figure84.1Cash and equivalents, Q1 FY2024, at 2024-03-31$84.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-04-26, accession 0001213900-24-036699.Report this figure86.0Cash and equivalents, Q2 FY2024, at 2024-06-30$86.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-05, accession 0001213900-24-065239.Report this figure78.7Cash and equivalents, Q3 FY2024, at 2024-09-30$78.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figure72.9Cash and equivalents, FY2024, at 2024-12-31$72.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure65.3Cash and equivalents, Q1 FY2025, at 2025-03-31$65.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure59.9Cash and equivalents, Q2 FY2025, at 2025-06-30$59.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-08, accession 0001213900-25-073743.Report this figure53.4Cash and equivalents, Q3 FY2025, at 2025-09-30$53.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure48.0Cash and equivalents, FY2025, at 2025-12-31$48.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure42.1Cash and equivalents, Q1 FY2026, at 2026-03-31$42.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure36.5Cash and equivalents, Q2 FY2026, at 2026-06-30$36.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Current assets$m85.6Current assets, Q3 FY2023, at 2023-09-30$85.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0001213900-23-082459.Report this figure78.3Current assets, FY2023, at 2023-12-31$78.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001213900-25-026371.Report this figure85.4Current assets, Q1 FY2024, at 2024-03-31$85.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-04-26, accession 0001213900-24-036699.Report this figure87.1Current assets, Q2 FY2024, at 2024-06-30$87.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-05, accession 0001213900-24-065239.Report this figure79.5Current assets, Q3 FY2024, at 2024-09-30$79.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figure74.5Current assets, FY2024, at 2024-12-31$74.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure66.5Current assets, Q1 FY2025, at 2025-03-31$66.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure61.0Current assets, Q2 FY2025, at 2025-06-30$61.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-08, accession 0001213900-25-073743.Report this figure54.4Current assets, Q3 FY2025, at 2025-09-30$54.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure49.4Current assets, FY2025, at 2025-12-31$49.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure43.3Current assets, Q1 FY2026, at 2026-03-31$43.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure37.7Current assets, Q2 FY2026, at 2026-06-30$37.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Total assets$m88.9Total assets, Q3 FY2023, at 2023-09-30$88.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0001213900-23-082459.Report this figure81.4Total assets, FY2023, at 2023-12-31$81.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001213900-25-026371.Report this figure88.4Total assets, Q1 FY2024, at 2024-03-31$88.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-04-26, accession 0001213900-24-036699.Report this figure89.9Total assets, Q2 FY2024, at 2024-06-30$89.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-05, accession 0001213900-24-065239.Report this figure82.1Total assets, Q3 FY2024, at 2024-09-30$82.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figure76.9Total assets, FY2024, at 2024-12-31$76.9m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure68.6Total assets, Q1 FY2025, at 2025-03-31$68.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure63.0Total assets, Q2 FY2025, at 2025-06-30$63.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-08, accession 0001213900-25-073743.Report this figure56.2Total assets, Q3 FY2025, at 2025-09-30$56.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure51.8Total assets, FY2025, at 2025-12-31$51.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure45.4Total assets, Q1 FY2026, at 2026-03-31$45.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure40.2Total assets, Q2 FY2026, at 2026-06-30$40.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Current liabilities$m8.7Current liabilities, Q3 FY2023, at 2023-09-30$8.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0001213900-23-082459.Report this figure8.5Current liabilities, FY2023, at 2023-12-31$8.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001213900-25-026371.Report this figure8.1Current liabilities, Q1 FY2024, at 2024-03-31$8.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-04-26, accession 0001213900-24-036699.Report this figure9.7Current liabilities, Q2 FY2024, at 2024-06-30$9.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-05, accession 0001213900-24-065239.Report this figure7.8Current liabilities, Q3 FY2024, at 2024-09-30$7.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figure8.1Current liabilities, FY2024, at 2024-12-31$8.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure7.1Current liabilities, Q1 FY2025, at 2025-03-31$7.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure8.3Current liabilities, Q2 FY2025, at 2025-06-30$8.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-08, accession 0001213900-25-073743.Report this figure6.8Current liabilities, Q3 FY2025, at 2025-09-30$6.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure8.0Current liabilities, FY2025, at 2025-12-31$8.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure7.3Current liabilities, Q1 FY2026, at 2026-03-31$7.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure9.3Current liabilities, Q2 FY2026, at 2026-06-30$9.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Total liabilities$m45.4Total liabilities, Q3 FY2023, at 2023-09-30$45.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0001213900-23-082459.Report this figure45.1Total liabilities, FY2023, at 2023-12-31$45.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001213900-25-026371.Report this figure44.5Total liabilities, Q1 FY2024, at 2024-03-31$44.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-04-26, accession 0001213900-24-036699.Report this figure46.0Total liabilities, Q2 FY2024, at 2024-06-30$46.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-05, accession 0001213900-24-065239.Report this figure43.9Total liabilities, Q3 FY2024, at 2024-09-30$43.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figure44.1Total liabilities, FY2024, at 2024-12-31$44.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure43.0Total liabilities, Q1 FY2025, at 2025-03-31$43.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure44.0Total liabilities, Q2 FY2025, at 2025-06-30$44.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-08, accession 0001213900-25-073743.Report this figure42.4Total liabilities, Q3 FY2025, at 2025-09-30$42.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure43.9Total liabilities, FY2025, at 2025-12-31$43.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure43.1Total liabilities, Q1 FY2026, at 2026-03-31$43.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure9.9Total liabilities, Q2 FY2026, at 2026-06-30$9.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Shareholders' equity$m43.6Shareholders' equity, Q3 FY2023, at 2023-09-30$43.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figure36.4Shareholders' equity, FY2023, at 2023-12-31$36.4m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure43.9Shareholders' equity, Q1 FY2024, at 2024-03-31$43.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure43.8Shareholders' equity, Q2 FY2024, at 2024-06-30$43.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure38.2Shareholders' equity, Q3 FY2024, at 2024-09-30$38.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure32.8Shareholders' equity, FY2024, at 2024-12-31$32.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure25.7Shareholders' equity, Q1 FY2025, at 2025-03-31$25.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure19.0Shareholders' equity, Q2 FY2025, at 2025-06-30$19.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure13.8Shareholders' equity, Q3 FY2025, at 2025-09-30$13.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure7.8Shareholders' equity, FY2025, at 2025-12-31$7.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure2.3Shareholders' equity, Q1 FY2026, at 2026-03-31$2.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure30.3Shareholders' equity, Q2 FY2026, at 2026-06-30$30.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure

Cash flow

Operating cash flow−$5.2m, Q2 FY2026
Capital expenditure$478.0k, Q2 FY2026
Actinium Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(11.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$11.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001213900-24-098534. Derived: 9-month figure less the 6-month figure.Report this figure(7.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$7.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001213900-25-026371. Derived: 12-month figure less the 9-month figure.Report this figure(7.4)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$7.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure(8.0)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$8.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-08, accession 0001213900-25-073743. Derived: 6-month figure less the 3-month figure.Report this figure(12.0)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$12.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001213900-25-110979. Derived: 9-month figure less the 6-month figure.Report this figure(5.8)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figure(7.6)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$7.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure(5.4)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001213900-26-086769. Derived: 6-month figure less the 3-month figure.Report this figure(6.3)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$6.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001213900-25-110979. Derived: 9-month figure less the 6-month figure.Report this figure(5.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figure(5.9)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$5.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure(5.2)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001213900-26-086769. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$30.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-14, accession 0001213900-24-098534. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001213900-25-026371. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-08, accession 0001213900-25-073743. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001213900-25-110979. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reported0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure0.5Capital expenditure, Q2 FY2026, three months to 2026-06-30$478.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0001213900-26-086769. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)31.41m, Q2 FY2026
Actinium Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares25.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3025,164,599 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0001213900-23-082459.Report this figure25.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3125,696,623 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-04-26, accession 0001213900-24-036699.Report this figure26.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3026,217,910 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-05, accession 0001213900-24-065239.Report this figure27.1Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3027,058,397 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001213900-24-098534.Report this figure27.9Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3127,886,486 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-09, accession 0001213900-25-041614.Report this figure30.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3030,103,063 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-08, accession 0001213900-25-073743.Report this figure31.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3031,071,297 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure31.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3131,195,891 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure31.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3031,195,891 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure31.2Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3031,195,891 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure31.2Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3131,237,681 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure31.4Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3031,406,740 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure

Shares outstanding: 31.44mShares outstanding, period not labelled, at 2026-08-0631,441,436 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure at Aug 6, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.